Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8<sup>+</sup> T cell cytotoxicity over BEMPEG+RT.

J Immunother Cancer · 2022 · PMC9021762 · PMID 35444059

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Supplementary data jitc-2021-004218supp005.pdf We observed reduced AH1-A5 + CD8 + T cell frequency after BEMPEG+RT plus IFNAR blockade that did not reach statistical significance ( figure 4B ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.